Our Network Imfinzi plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone Tags: #Research #Oncology #Medical Oncology #Clinical research #AstraZeneca Trial will continue to assess primary endpoint of event-free survival.
